Avadel Pharmaceuticals (AVDL) said Tuesday it expects to generate "sustainable positive cash flow" in 2025, driven by continued growth in patient demand for its narcolepsy drug, Lumryz.

The company said during its March results that it expects to generate $240 million to $260 million in net product revenue and cash flow of $20 million and $40 million during 2025, as the number of patients on Lumryz is set to rise to 3,300 to 3,500.

The company said key metrics including patient enrollments, therapy starts, persistency, and total patients on treatment all improved in Q1 compared to Q4 2024. Avadel also said enrollment in its phase 3 Revitalyz trial of Lumryz for idiopathic hypersomnia remains on track for completion in H2.

In connection with potential US tariff changes, Avadel said it developed a diversified supply chain over the past three years for Lumryz. The drug's active pharmaceutical ingredient is manufactured entirely in the US, with final production and packaging split between US and European facilities.

Avadel provided the updates at the latest annual Needham virtual healthcare conference.

Price: 6.73, Change: +0.04, Percent Change: +0.64